Metabolic factors and chronic hepatitis C: A complex interplay

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Macaluso, Fabio Salvatore ^a   Maida, Marcello ^a   Minissale, Maria Giovanna ^a   Li Vigni, Teresa ^a   Attardo, Simona ^a   Orlando, Emanuele ^a   Petta, Salvatore ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FRUCTOSE; LIPOPROTEIN; VITAMIN D;

ATHEROSCLEROSIS; COFFEE; DISEASE COURSE; GENOTYPE; HEPATITIS C; HUMAN; HYPERURICEMIA; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MENOPAUSE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; REPRODUCTION; REVIEW; STEATOSIS; GENETICS; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; RISK FACTOR; VIROLOGY; COMPLICATION;

DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; RISK FACTORS;

EID: 84881530517     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/564645     Document Type: Review

References (165)

1. Lavanchy D., The global burden of hepatitis C. Liver International 2009 29 1 74 81 2-s2.0-59149085501 10.1111/j.1478-3231.2008.01934.x
2. Petta S., Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors? Digestive and Liver Disease 2012 44 5 359 360 2-s2.0-84859209998 10.1016/j.dld.2012.02.001
3. Bugianesi E., Salamone F., Negro F., The interaction of metabolic factors with HCV infection: does it matter? Journal of Hepatology 2012 56 supplement 1 S56 S65 2-s2.0-84856474979 10.1016/S0168-8278(12)60007-5
4. Bugianesi E., McCullough A. J., Marchesini G., Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005 42 5 987 1000 2-s2.0-30944455145 10.1002/hep.20920 (Pubitemid 43112663)
5. Zimmet P., Alberti K. G. M. M., Global and societal implications of the diabetes epidemic. Nature 2001 414 6865 782 787 2-s2.0-0035856920 10.1038/414782a (Pubitemid 34000780)
6. Petta S., Cammà C., Marco V. D., Alessi N., Cabibi D., Caldarella R., Licata A., Massenti F., Tarantino G., Marchesini G., Craxì A., Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. American Journal of Gastroenterology 2008 103 5 1136 1144 2-s2.0-43549124805 10.1111/j.1572-0241.2008.01813.x (Pubitemid 351677995)
7. Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Tsukamoto K., Kimura S., Moriya K., Koike K., Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126 3 840 848 2-s2.0-1542287381 10.1053/j.gastro.2003.11. 056 (Pubitemid 38298332)
8. Moucari R., Asselah T., Cazals-Hatem D., Voitot H., Boyer N., Ripault M.-P., Sobesky R., Martinot-Peignoux M., Maylin S., Nicolas-Chanoine M.-H., Paradis V., Vidaud M., Valla D., Bedossa P., Marcellin P., Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008 134 2 416 423 2-s2.0-38649120719 10.1053/j.gastro.2007.11.010 (Pubitemid 351181308)
9. Negro F., Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010 59 9 1279 1287 2-s2.0-77956115313 10.1136/gut.2009.192732
10. Hui J. M., Sud A., Farrell G. C., Bandara P., Byth K., Kench J. G., McCaughan G. W., George J., Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003 125 6 1695 1704 2-s2.0-0345655291 10.1053/j.gastro.2003.08.032 (Pubitemid 37500434)
11. Arase Y., Suzuki F., Suzuki Y., Akuta N., Kobayashi M., Kawamura Y., Yatsuji H., Sezaki H., Hosaka T., Hirakawa M., Ikeda K., Kumada H., Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009 49 3 739 744 2-s2.0-63349097919 10.1002/hep.22703
12. Vanni E., Abate M. L., Gentilcore E., Hickman I., Gambino R., Cassader M., Smedile A., Ferrannini E., Rizzetto M., Marchesini G., Gastaldelli A., Bugianesi E., Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009 50 3 697 706 2-s2.0-70349247875 10.1002/hep.23031
13. Parvaiz F., Manzoor S., Tariq H., Javed F., Fatima K., Qadri I., Hepatitis C virus infection: molecular pathways to insulin resistance. Virology Journal 2011 8, article 474 2-s2.0-80054107342 10.1186/1743-422X-8-474
14. Sheikh M. Y., Choi J., Qadri I., Friedman J. E., Sanyal A. J., Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008 47 6 2127 2133 2-s2.0-46249111657 10.1002/hep.22269 (Pubitemid 351945577)
15. Stepanova M., Rafiq N., Younossi Z. M., Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010 59 10 1410 1415 2-s2.0-77957196987 10.1136/gut.2010.213553
16. Cua I. H. Y., Hui J. M., Kench J. G., George J., Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008 48 3 723 731 2-s2.0-51349122296 10.1002/hep.22392
17. Cammà C., Bruno S., Di Marco V., Di Bona D., Rumi M., Vinci M., Rebucci C., Cividini A., Pizzolanti G., Minola E., Mondelli M. U., Colombo M., Pinzello G., Craxì A., Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006 43 1 64 71 2-s2.0-33644806684 10.1002/hep.20983 (Pubitemid 43738959)
18. Browning J. D., Horton J. D., Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 2004 114 2 147 152 2-s2.0-4043077961 10.1172/JCI200422422 (Pubitemid 39071617)
19. Svegliati-Baroni G., Ridolfi F., Di Sario A., Casini A., Marucci L., Gaggiotti G., Orlandoni P., Macarri G., Perego L., Benedetti A., Folli F., Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999 29 6 1743 1751 2-s2.0-0032994264 10.1002/hep.510290632 (Pubitemid 29247048)
20. Giordanino C., Ceretto S., Bo S., Smedile A., Ciancio A., Bugianesi E., Pellicano R., Fagoonee S., Versino E., Costa G., Arese D., Sacco M., Rizzetto M., Saracco G., Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study. Digestive and Liver Disease 2012 44 5 406 412 2-s2.0-84859213032 10.1016/j.dld.2011.12.003
21. Cammà C., Petta S., Di Marco V., Bronte F., Ciminnisi S., Licata G., Peralta S., Simone F., Marchesini G., Craxì A., Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology 2009 49 1 195 203 2-s2.0-58949093452 10.1002/hep.22655
22. Vincent M. A., Montagnani M., Quon M. J., Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Current Diabetes Reports 2003 3 4 279 288 2-s2.0-0141671792 (Pubitemid 38906783)
23. Iwakiri Y., Groszmann R. J., Vascular endothelial dysfunction in cirrhosis. Journal of Hepatology 2007 46 5 927 934 2-s2.0-34047175876 10.1016/j.jhep.2007.02.006 (Pubitemid 46529052)
24. Chen C.-L., Yang H.-I., Yang W.-S., Liu C.-J., Chen P.-J., You S.-L., Wang L.-Y., Sun C.-A., Lu S.-N., Chen D.-S., Chen C.-J., Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008 135 1 111 121 2-s2.0-46049119423 10.1053/j.gastro.2008.03.073 (Pubitemid 351899021)
25. Nkontchou G., Bastard J.-P., Ziol M., Aout M., Cosson E., Ganne-Carrie N., Grando-Lemaire V., Roulot D., Capeau J., Trinchet J.-C., Vicaut E., Beaugrand M., Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. Journal of Hepatology 2010 53 5 827 833 2-s2.0-77957365464 10.1016/j.jhep.2010.04.035
26. Petta S., Craxì A., Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Current Pharmaceutical Design 2010 16 6 741 752 2-s2.0-77950231570 10.2174/ 138161210790883787
27. Romero-Gómez M., Del Mar Viloria M., Andrade R. J., Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 636 641 (Pubitemid 40585366)
28. Conjeevaram H. S., Kleiner D. E., Everhart J. E., Hoofnagle J. H., Zacks S., Afdhal N. H., Wahed A. S., Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007 45 1 80 87 2-s2.0-33846463006 10.1002/hep.21455 (Pubitemid 46144367)
29. Poustchi H., Negro F., Hui J., Cua I. H. Y., Brandt L. R., Kench J. G., George J., Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of Hepatology 2008 48 1 28 34 2-s2.0-36549032819 10.1016/j.jhep.2007.07.026 (Pubitemid 350191982)
30. De Nicola S., Aghemo A., Grazia Rumi M., Galmozzi E., Valenti L., Soffredini R., De Francesco R., Prati G. M., D'Ambrosio R., Cheroni C., Donato M. F., Colombo M., Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012 55 2 336 342 2-s2.0-84856378581 10.1002/hep.24683
31. Deltenre P., Louvet A., Lemoine M., Mourad A., Fartoux L., Moreno C., Henrion J., Mathurin P., Serfaty L., Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. Journal of Hepatology 2011 55 6 1187 1194 2-s2.0-79960824576 10.1016/j.jhep.2011.03.010
32. Grasso A., Malfatti F., Leo P. D., Martines H., Fabris P., Toscanini F., Anselmo M., Menardo G., Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. Journal of Hepatology 2009 51 6 984 990 2-s2.0-71549129264 10.1016/j.jhep.2009.07.008
33. Franceschini L., Realdon S., Marcolongo M., Mirandola S., Bortoletto G., Alberti A., Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance? Hepatology 2011 54 2 484 494 2-s2.0-79960733447 10.1002/hep.24394
34. Fattovich G., Svegliati Baroni G., Pasino M., Pierantonelli I., Covolo L., Ieluzzi D., Passigato N., Tonon A., Faraci M. G., Guido M., Negro F., Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. Digestive and Liver Disease 2012 44 5 419 425 2-s2.0-84859209957 10.1016/j.dld.2011.12.006
35. Petta S., Amato M., Cabibi D., Cammà C., Di Marco V., Giordano C., Galluzzo A., Craxì A., Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010 52 5 1543 1552 2-s2.0-78049516225 10.1002/hep.23859
36. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., Younossi Z., Albrecht J., Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003 38 1 75 85 2-s2.0-0038122773 10.1053/jhep.2003.50267 (Pubitemid 36775798)
37. Petta S., Rosso C., Leung R., Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clinical Gastroenterology and Hepatology 2013 11 311 317
38. Serfaty L., Forns X., Goeser T., Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1. Gut 2012 61 1473 1480 10.1136/gutjnl-2011-300749
39. Younossi Z., Negro F., Serfaty L., The homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology 2013 10.1002/hep.26437
40. Adinolfi L. E., Gambardella M., Andreana A., Tripodi M.-F., Utili R., Ruggiero G., Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 6 1358 1364 2-s2.0-0034987263 10.1053/jhep.2001. 24432 (Pubitemid 32496971)
41. Thomopoulos K. C., Arvaniti V., Tsamantas A. C., Dimitropoulou D., Gogos C. A., Siagris D., Theocharis G. J., Labropoulou-Karatza C., Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. European Journal of Gastroenterology and Hepatology 2006 18 3 233 237 2-s2.0-33644593865 10.1097/00042737-200603000-00002
42. Lonardo A., Adinolfi L. E., Loria P., Carulli N., Ruggiero G., Day C. P., Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extraepatic disease. Gastroenterology 2004 126 2 586 597 2-s2.0-0842300373 10.1053/j.gastro.2003.11.020 (Pubitemid 38182315)
43. Mihm S., Fayyazi A., Hartmann H., Ramadori G., Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997 25 3 735 739 2-s2.0-0031055840 10.1002/hep.510250340 (Pubitemid 27106462)
44. Abid K., Pazienza V., De Gottardi A., Rubbia-Brandt L., Conne B., Pugnale P., Rossi C., Mangia A., Negro F., An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. Journal of Hepatology 2005 42 5 744 751 2-s2.0-17044382863 10.1016/j.jhep.2004.12.034
45. Piodi A., Chouteau P., Lerat H., Hézode C., Pawlotsky J.-M., Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology 2008 48 1 16 27 2-s2.0-47149095922 10.1002/hep.22288 (Pubitemid 351975527)
46. Negro F., Mechanisms and significance of liver steatosis in hepatitis C virus infection. World Journal of Gastroenterology 2006 12 42 6756 6765 2-s2.0-33751372117 (Pubitemid 44811395)
47. Larter C. Z., Farrell G. C., Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? Journal of Hepatology 2006 44 2 253 261 2-s2.0-30444461216 10.1016/j.jhep.2005.11.030 (Pubitemid 43071224)
48. Petta S., Cammà C., Di Marco V., Alessi N., Barbaria F., Cabibi D., Caldarella R., Ciminnisi S., Licata A., Massenti M. F., Mazzola A., Tarantino G., Marchesini G., Craxì A., Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. Hepatology 2008 48 1 28 37 2-s2.0-47149104844 10.1002/hep.22316 (Pubitemid 351975528)
49. Petta S., Tripodo C., Grimaudo S., Cabibi D., Cammà C., Di Cristina A., Di Marco V., Di Vita G., Ingrao S., Mazzola A., Marchesini G., Pipitone R., Craxì A., High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Digestive and Liver Disease 2011 43 5 404 410 2-s2.0-79953271176 10.1016/j.dld.2010.12.013
50. Mihm S., Hepatitis C virus, diabetes and steatosis: clinical evidence in favor of a linkage and role of genotypes. Digestive Diseases 2010 28 1 280 284 2-s2.0-77952569599 10.1159/000282103
51. Patton H. M., Patel K., Behling C., Bylund D., Blatt L. M., Vallée M., Heaton S., Conrad A., Pockros P. J., McHutchison J. G., The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. Journal of Hepatology 2004 40 3 484 490 2-s2.0-10744227418 10.1016/j.jhep.2003.11.004 (Pubitemid 38230851)
52. Leandro G., Mangia A., Hui J., Fabris P., Rubbia-Brandt L., Colloredo G., Adinolfi L. E., Asselah T., Jonsson J. R., Smedile A., Terrault N., Pazienza V., Giordani M. T., Giostra E., Sonzogni A., Ruggiero G., Marcellin P., Powell E. E., George J., Negro F., Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006 130 6 1636 1642 2-s2.0-33646529840 10.1053/j.gastro.2006. 03.014
53. Fartoux L., Chazouillères O., Wendum D., Poupon R., Serfaty L., Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005 41 1 82 87 2-s2.0-11244323975 10.1002/hep.20519 (Pubitemid 40066385)
54. Castéra L., Hézode C., Roudot-Thoraval F., Bastie A., Zafrani E.-S., Pawlotsky J.-M., Dhumeaux D., Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003 52 2 288 292 2-s2.0-0037301686 10.1136/gut.52.2.288 (Pubitemid 36115074)
55. Okuda M., Li K., Beard M. R., Showalter L. A., Scholle F., Lemon S. M., Weinman S. A., Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002 122 2 366 375 2-s2.0-0036165333 (Pubitemid 34116988)
56. Lerat H., Honda M., Beard M. R., Loesch K., Sun J., Yang Y., Okuda M., Gosert R., Xiao S., Weinman S. A., Lemon S. M., Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002 122 2 352 365 2-s2.0-0036158719 (Pubitemid 34116987)
57. Kitase A., Hino K., Furutani T., Okuda M., Gondo T., Hidaka I., Hara Y., Yamaguchi Y., Okita K., In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. Journal of Gastroenterology 2005 40 6 617 624 2-s2.0-22844447076 10.1007/s00535-005-1596-x (Pubitemid 41038791)
58. Gochee P. A., Jonsson J. R., Clouston A. D., Pandeya N., Purdie D. M., Powell E. E., Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor- α and cytochrome P450 2E1. Journal of Gastroenterology and Hepatology 2003 18 4 386 392 2-s2.0-0038557186 10.1046/j.1440-1746.2003.02984.x (Pubitemid 36549548)
59. Hora C., Negro F., Leandro G., Is connective tissue growth factor (CTGF) the missing link between steatosis, insulin resistance and fibrosis in patients with chronic hepatitis C? Journal of Hepatology 2006 44 supplement 2 S199
60. Aleffi S., Petrai I., Bertolani C., Parola M., Colombatto S., Novo E., Vizzutti F., Anania F. A., Milani S., Rombouts K., Laffi G., Pinzani M., Marra F., Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005 42 6 1339 1348 2-s2.0-32944478021 10.1002/hep.20965 (Pubitemid 43260036)
61. Walsh M. J., Vanags D. M., Clouston A. D., Richardson M. M., Purdie D. M., Jonsson J. R., Powell E. E., Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004 39 5 1230 1238 2-s2.0-2342559886 10.1002/hep.20179 (Pubitemid 38569044)
62. Seidel N., Volkmann X., Länger F., Flemming P., Manns M. P., Schulze-Osthoff K., Bantel H., The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 2005 42 1 113 120 2-s2.0-21344442145 10.1002/hep.20747 (Pubitemid 40911318)
63. Pekow J. R., Bhan A. K., Zheng H., Chung R. T., Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007 109 12 2490 2496 2-s2.0-34250339305 10.1002/cncr.22701 (Pubitemid 46908652)
64. Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Ishibashi K., Matsuura Y., Miyamura T., Koike K., Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. Journal of General Virology 1997 78 7 1527 1531 2-s2.0-0030859121 (Pubitemid 27343089)
65. Moradpour D., Englert C., Wakita T., Wands J. R., Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996 222 1 51 63 2-s2.0-0030218609 10.1006/viro.1996.0397 (Pubitemid 26281358)
66. Tanaka N., Moriya K., Kiyosawa K., Koike K., Gonzalez F. J., Aoyama T., PPAR α activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. Journal of Clinical Investigation 2008 118 2 683 694 2-s2.0-38849184816 10.1172/JCI33594 (Pubitemid 351206557)
67. Lim W. S., Ng D. L., Kor S. B., Tumour necrosis factor alpha down-regulates the expression of PPARalpha in human hepatocarcinoma HepG2 cells by activation of NF-kB pathway. Cytokine 2013 61 266 274 10.1016/j.cyto.2012.10. 007
68. Walsh M. J., Jonsson J. R., Richardson M. M., Lipka G. M., Purdie D. M., Clouston A. D., Powell E. E., Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006 55 4 529 535 2-s2.0-33645114359 10.1136/gut.2005.069674
69. Kotronen A., Peltonen M., Hakkarainen A., Sevastianova K., Bergholm R., Johansson L. M., Lundbom N., Rissanen A., Ridderstråle M., Groop L., Orho-Melander M., Yki-Järvinen H., Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009 137 3 865 872 2-s2.0-69249087403 10.1053/j.gastro.2009.06.005
70. Valenti L., Al-Serri A., Daly A. K., Enrico Galmozzi E. G., Rametta R., Dongiovanni P., Nobili V., Mozzi E., Roviaro G., Vanni E., Bugianesi E., Maggioni M., LudovicaFracanzani A., Fargion S., Day C. P., Homozygosity for the patatin-like phospholipase-3/adiponutrin i148 m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010 51 4 1209 1217 2-s2.0-77950607738 10.1002/hep.23622
71. Valenti L., Rumi M., Galmozzi E., Aghemo A., Del Menico B., De Nicola S., Dongiovanni P., Maggioni M., Fracanzani A. L., Rametta R., Colombo M., Fargion S., Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011 53 3 791 799 2-s2.0-79952222716 10.1002/hep.24123
72. Shoelson S. E., Herrero L., Naaz A., Obesity, inflammation, and insulin resistance. Gastroenterology 2007 132 6 2169 2180 2-s2.0-34247857663 10.1053/j.gastro.2007.03.059 (Pubitemid 46693756)
73. Després J.-P., Lemieux I., Abdominal obesity and metabolic syndrome. Nature 2006 444 7121 881 887 2-s2.0-33845886915 10.1038/nature05488 (Pubitemid 46024995)
74. Chan D. C., Watts G. F., Ng T. W. K., Hua J., Song S., Barrett P. H. R., Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes, Obesity and Metabolism 2006 8 6 698 702 2-s2.0-33749487086 10.1111/j.1463-1326.2005.00543.x (Pubitemid 44515568)
75. Thomas E. L., Hamilton G., Patel N., O'Dwyer R., Doré C. J., Goldin R. D., Bell J. D., Taylor-Robinson S. D., Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005 54 1 122 127 2-s2.0-10844240700 10.1136/gut.2003.036566 (Pubitemid 40007230)
76. van der Poorten D., Milner K.-L., Hui J., Hodge A., Trenell M. I., Kench J. G., London R., Peduto T., Chisholm D. J., George J., Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008 48 2 449 457 2-s2.0-49649096375 10.1002/hep.22350
77. González-Reimers E., Castellano-Higuera A., Alemán-Valls R., Alvarez-Argüelles H., De La Vega-Prieto M. J., Abreu-González P., López-Prieto J., Santolaria-Fernández F., Valladares-Parrilla F., Relation between body fat and liver fat accumulation and cytokine pattern in non-alcoholic patients with chronic HCV infection. Annals of Nutrition and Metabolism 2009 55 4 351 357 2-s2.0-70350152410 10.1159/000252351
78. Hourigan L. F., Macdonald G. A., Purdie D., Whitehall V. H., Shorthouse C., Clouston A., Powell E. E., Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999 29 4 1215 1219 2-s2.0-0032924020 (Pubitemid 29168757)
79. Amato M. C., Giordano C., Galia M., Criscimanna A., Vitabile S., Midiri M., Galluzzo A., Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010 33 4 920 922 2-s2.0-77953034355 10.2337/dc09-1825
80. Ticehurst J. R., Hamzeh F. M., Thomas D. L., Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. Journal of Clinical Microbiology 2007 45 8 2426 2433 2-s2.0-34548081220 10.1128/JCM.02448-06 (Pubitemid 47295469)
81. Chen W., Wong T., Tomlinson G., Krahn M., Heathcote E. J., Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. Journal of Hepatology 2008 49 5 711 717 2-s2.0-53249090462 10.1016/j.jhep.2008.05.013
82. Everhart J. E., Lok A. S., Kim H.-Y., Morgan T. R., Lindsay K. L., Chung R. T., Bonkovsky H. L., Ghany M. G., Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009 137 2 549 557 2-s2.0-67651095837 10.1053/j.gastro.2009.05.007
83. Poordad F., Bronowicki J. P., Gordon S. C., Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012 143 608 618
84. Völzke H., Schwahn C., Wolff B., Mentel R., Robinson D. M., Kleine V., Felix S. B., John U., Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 2004 174 1 99 103 2-s2.0-2342460188 10.1016/j.atherosclerosis.2004.01.010 (Pubitemid 38595446)
85. Lee M. H., Yang H. I., Lu S. N., Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. Journal of Infectious Diseases 2012 206 469 477
86. Boddi M., Abbate R., Chellini B., Giusti B., Solazzo V., Soft F., Pratesi G., Pratesi C., Gensini G., Zignego A. L., HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Digestive and Liver Disease 2007 39 1 S55 S60 2-s2.0-34948875228 10.1016/S1590-8658(07)80012-0 (Pubitemid 47528195)
87. Targher G., Bertolini L., Padovani R., Rodella S., Arcaro G., Day C., Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. Journal of Hepatology 2007 46 6 1126 1132 2-s2.0-34247636128 10.1016/j.jhep.2007.01.021 (Pubitemid 46669732)
88. Ishizaka Y., Ishizaka N., Takahashi E., Unuma T., Tooda E.-I., Hashimoto H., Nagai R., Yamakado M., Association between hepatitis C virus core protein and carotid atherosclerosis. Circulation Journal 2003 67 1 26 30 2-s2.0-12244261582 10.1253/circj.67.26 (Pubitemid 36119617)
89. Ishizaka N., Ishizaka Y., Takahashi E., Tooda E.-I., Hashimoto H., Nagai R., Yamakado M., Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. The Lancet 2002 359 9301 133 135 2-s2.0-0037065523 10.1016/S0140-6736(02)07339-7 (Pubitemid 34112545)
90. Marzouk D., Sass J., Bakr I., El Hosseiny M., Abdel-Hamid M., Rekacewicz C., Chaturvedi N., Mohamed M. K., Fontanet A., Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007 56 8 1105 1110 2-s2.0-34547221898 10.1136/gut.2006.091983 (Pubitemid 47123241)
91. Petta S., Torres D., Fazio G., Cammà C., Cabibi D., Di Marco V., Licata A., Marchesini G., Mazzola A., Parrinello G., Novo S., Licata G., Craxì A., Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 2012 55 5 1317 1323 2-s2.0-84859994950 10.1002/hep.25508
92. Lee M.-H., Yang H.-I., Wang C.-H., Jen C.-L., Yeh S.-H., Liu C.-J., You S.-L., Chen W. J., Chen C.-J., Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010 41 12 2894 2900 2-s2.0-78650419996 10.1161/STROKEAHA.110.598136
93. Boddi M., Abbate R., Chellini B., Giusti B., Giannini C., Pratesi G., Rossi L., Pratesi C., Gensini G. F., Paperetti L., Zignego A. L., Hepatitis C virus RNA localization in human carotid plaques. Journal of Clinical Virology 2010 47 1 72 75 2-s2.0-72149090654 10.1016/j.jcv.2009.10.005
94. Adinolfi L. E., Restivo L., Zampino R., Guerrera B., Lonardo A., Ruggiero L., Riello F., Loria P., Florio A., Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012 221 2 496 502 2-s2.0-84858707788 10.1016/j.atherosclerosis.2012.01.051
95. Mostafa A., Mohamed M. K., Saeed M., Hasan A., Fontanet A., Godsland I., Coady E., Esmat G., El-Hoseiny M., Abdul-Hamid M., Hughes A., Chaturvedi N., Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010 59 8 1135 1140 2-s2.0-77954712562 10.1136/gut.2009.202317
96. Miyajima I., Kawaguchi T., Fukami A., Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. Journal of Gastroenterology 2013 48 93 100
97. Younossi Z. M., Stepanova M., Nader F., Younossi Z., Elsheikh E., Associations of chronic hepatitis C with metabolic and cardiac outcomes. Alimentary Pharmacology & Therapeutics 2013 37 647 652 10.1111/apt.12234
98. Kitson M. T., Roberts S. K., D-Livering the message: the importance of vitamin D status in chronic liver disease. Journal of Hepatology 2012 57 897 909
99. Petta S., Cammà C., Scazzone C., Tripodo C., Marco V. D., Bono A., Cabibi D., Licata G., Porcasi R., Marchesini G., Craxí A., Low vitamin d serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010 51 4 1158 1167 2-s2.0-77950624679 10.1002/hep.23489
100. Bitetto D., Fattovich G., Fabris C., Ceriani E., Falleti E., Fornasiere E., Pasino M., Ieluzzi D., Cussigh A., Cmet S., Pirisi M., Toniutto P., Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011 53 4 1118 1126 2-s2.0-79953733132 10.1002/hep.24201
101. Kitson M. T., Dore G. J., George J., Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology 2013 58 467 472
102. Baur K., Mertens J. C., Schmitt J., Iwata R., Stieger B., Eloranta J. J., Frei P., Stickel F., Dill M. T., Seifert B., Bischoff Ferrari H. A., von Eckardstein A., Bochud P.-Y., Müllhaupt B., Geier A., Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin D Receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver International 2012 32 4 635 643 2-s2.0-84858281844 10.1111/j.1478-3231.2011.02674.x
103. Lange C. M., Bojunga J., Ramos-Lopez E., Von Wagner M., Hassler A., Vermehren J., Herrmann E., Badenhoop K., Zeuzem S., Sarrazin C., Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Journal of Hepatology 2011 54 5 887 893 2-s2.0-79954669573 10.1016/j.jhep.2010.08.036
104. Willheim M., Thien R., Schrattbauer K., Bajna E., Holub M., Gruber R., Baier K., Pietschmann P., Reinisch W., Scheiner O., Peterlik M., Regulatory effects of 1 α25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. Journal of Clinical Endocrinology and Metabolism 1999 84 10 3739 3744 2-s2.0-0033237649 (Pubitemid 30645234)
105. Timms P. M., Mannan N., Hitman G. A., Noonan K., Mills P. G., Syndercombe-Court D., Aganna E., Price C. P., Boucher B. J., Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? Quarterly Journal of Medicine 2002 95 12 787 796 2-s2.0-0036924775 10.1093/qjmed/95.12.787 (Pubitemid 36032948)
106. Cigolini M., Iagulli M. P., Miconi V., Galiotto M., Lombardi S., Targher G., Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006 29 3 722 724 2-s2.0-33744985849 (Pubitemid 44115386)
107. Cantorna M. T., Zhu Y., Froicu M., Wittke A., Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. The American Journal of Clinical Nutrition 2004 80 6 1717 1720 2-s2.0-16544367410
108. Abu-Mouch S., Fireman Z., Jarchovsky J., Assy N., The beneficial effect of vitamin D combined eg interferon and ribavirin for chronic HCV infection. Hepatology 2009 50 LB20
109. Wang T. J., Zhang F., Richards J. B., Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet 2010 376 180 188
110. Petta S., Grimaudo S., Di Marco V., Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. Journal of Viral Hepatitis 2013 20 7 486 493
111. Petta S., Ferraro D., Cammà C., Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antiviral Therapy 2012 17 823 831
112. Abu-Mouch S., Fireman Z., Jarchovsky J., Zeina A.-R., Assy N., Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World Journal of Gastroenterology 2011 17 47 5184 5190 2-s2.0-83755196636 10.3748/wjg.v17.i47.5184
113. Nimer A., Mouch A., Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World Journal of Gastroenterology 2012 18 8 800 805 2-s2.0-84857532001 10.3748/wjg.v18.i8.800
114. Von Essen M. R., Kongsbak M., Schjerling P., Olgaard K., Ødum N., Geisler C., Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nature Immunology 2010 11 4 344 349 2-s2.0-77949873898 10.1038/ni.1851
115. Conte D., Fraquelli M., Prati D., Colucci A., Minola E., Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV
116. Poynard T., Bedossa P., Opolon P., Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet 1997 349 9055 825 832 2-s2.0-0030933395 10.1016/S0140-6736(96)07642-8 (Pubitemid 27129209)
117. Deuffic-Burban S., Poynard T., Valleron A.-J., Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. Journal of Viral Hepatitis 2002 9 2 114 122 2-s2.0-0036902302 10.1046/j.1365-2893.2002. 00340.x (Pubitemid 36002474)
118. Di Martino V., Lebray P., Myers R. P., Pannier E., Paradis V., Charlotte F., Moussalli J., Thabut D., Buffet C., Poynard T., Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004 40 6 1426 1433 2-s2.0-10644278813 10.1002/hep.20463 (Pubitemid 39657018)
119. Villa E., Vukotic R., Cammà C., Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS ONE 2012 7 e44624
120. McHutchison J. G., Lawitz E. J., Shiffman M. L., Muir A. J., Galler G. W., McCone J., Nyberg L. M., Lee W. M., Ghalib R. H., Schiff E. R., Galati J. S., Bacon B. R., Davis M. N., Mukhopadhyay P., Koury K., Noviello S., Pedicone L. D., Brass C. A., Albrecht J. K., Sulkowski M. S., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New England Journal of Medicine 2009 361 6 580 593 2-s2.0-68249154875 10.1056/NEJMoa0808010
121. Conjeevaram H. S., Fried M. W., Jeffers L. J., Terrault N. A., Wiley-Lucas T. E., Afdhal N., Brown R. S., Belle S. H., Hoofnagle J. H., Kleiner D. E., Howell C. D., Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006 131 2 470 477 2-s2.0-33746535101 10.1053/j.gastro.2006.06.008 (Pubitemid 44142464)
122. Villa E., Karampatou A., Camm C., Di Leo A., Luongo M., Ferrari A., Petta S., Losi L., Taliani G., Trande P., Lei B., Graziosi A., Bernabucci V., Critelli R., Pazienza P., Rendina M., Antonelli A., Francavilla A., Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011 140 3 818 829 2-s2.0-79952308232 10.1053/j.gastro.2010.12.027
123. Villa E., Cammà C., Di Leo A., Karampatou A., Enea M., Gitto S., Bernabucci V., Losi L., De Maria N., Lei B., Ferrari A., Vukotic R., Vignoli P., Rendina M., Francavilla A., Peginterferon- α -2B plus ribavirin is more effective than peginterferon- α 2A plus ribavirin in menopausal women with chronic hepatitis C. Journal of Viral Hepatitis 2012 19 640 649 2-s2.0-84858182173 10.1111/j.1365-2893.2012.01593.x
124. Cieloszyk K., Hartel D., Moskaleva G., Schoenbaum E. E., Effects of hepatitis C virus infection on menopause status and symptoms. Menopause 2009 16 2 401 406 2-s2.0-67649316368 10.1097/gme.0b013e318186d7cf
125. Bray G. A., Nielsen S. J., Popkin B. M., Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. American Journal of Clinical Nutrition 2004 79 4 537 543 2-s2.0-2142815151 (Pubitemid 41103894)
126. Tetri L. H., Basaranoglu M., Brunt E. M., Yerian L. M., Neuschwander-Tetri B. A., Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. American Journal of Physiology 2008 295 5 G987 G995 2-s2.0-57349137214 10.1152/ajpgi.90272.2008
127. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J. L., Diehl A. M., Johnson R. J., Abdelmalek M. F., Fructose consumption as a risk factor for non-alcoholic fatty liver disease. Journal of Hepatology 2008 48 6 993 999 2-s2.0-43049170503 10.1016/j.jhep.2008.02.011
128. Aeberli I., Hochuli M., Gerber P. A., Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial. Diabetes Care 2013 36 150 156
129. Lin W. T., Huang H. L., Huang M. C., Effects on uric acid, body mass index and blood pressure in adolescents of consuming beverages sweetened with high-fructose corn syrup. International Journal of Obesity 2012 37 532 539
130. Odegaard A. O., Choh A. C., Czerwinski S. A., Towne B., Demerath E. W., Sugar-sweetened and diet beverages in relation to visceral adipose tissue. Obesity 2012 20 3 689 691 2-s2.0-84857662188 10.1038/oby.2011.277
131. Abdelmalek M. F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R. J., Diehl A. M., Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010 51 6 1961 1971 2-s2.0-77952692915 10.1002/hep.23535
132. Tyson G. L., Richardson P. A., White D. L., Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients. Journal of Clinical Gastroenterology 2013 47 6 545 552
133. Arnesen E., Huseby N. E., Brenn T., Try K., The Tromso heart study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scandinavian Journal of Clinical and Laboratory Investigation 1986 46 1 63 70 2-s2.0-0022560681 (Pubitemid 16105277)
134. Casiglia E., Spolaore P., Ginocchio G., Ambrosio G. B., Unexpected effects of coffee consumption on liver enzymes. European Journal of Epidemiology 1993 9 3 293 297 2-s2.0-0027274899 (Pubitemid 23238056)
135. Honjo S., Kono S., Coleman M. P., Shinchi K., Sakurai Y., Todoroki I., Umeda T., Wakabayashi K., Imanishi K., Nishikawa H., Ogawa S., Katsurada M., Nakagawa K., Yoshizawa N., Coffee consumption and serum aminotransferases in middle-aged Japanese men. Journal of Clinical Epidemiology 2001 54 8 823 829 2-s2.0-0034908692 10.1016/S0895-4356(01)00344-4 (Pubitemid 32722187)
136. Klatsky A. L., Morton C., Udaltsova N., Friedman G. D., Coffee, cirrhosis, and transaminase enzymes. Archives of Internal Medicine 2006 166 11 1190 1195 2-s2.0-33745038932 10.1001/archinte.166.11.1190 (Pubitemid 43877627)
137. Ruhl C. E., Everhart J. E., Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005 128 1 24 32 2-s2.0-11144257762 10.1053/j.gastro.2004.09. 075 (Pubitemid 40039955)
138. Freedman N. D., Everhart J. E., Lindsay K. L., Ghany M. G., Curto T. M., Shiffman M. L., Lee W. M., Lok A. S., Di Bisceglie A. M., Bonkovsky H. L., Hoefs J. C., Dienstag J. L., Morishima C., Abnet C. C., Sinha R., Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009 50 5 1360 1369 2-s2.0-72949092282 10.1002/hep.23162
139. Larsson S. C., Wolk A., Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007 132 5 1740 1745 2-s2.0-34247633571 10.1053/j.gastro.2007.03.044 (Pubitemid 46677953)
140. Freedman N. D., Curto T. M., Lindsay K. L., Wright E. C., Sinha R., Everhart J. E., Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011 140 7 1961 1969 2-s2.0-79958141959 10.1053/j.gastro.2011.02.061
141. Mancone C., Steindler C., Santangelo L., Simonte G., Vlassi C., Longo M. A., D'Offizi G., Di Giacomo C., Pucillo L. P., Amicone L., Tripodi M., Alonzi T., Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins. Gut 2011 60 3 378 386 2-s2.0-79851510198 10.1136/gut.2010.211292
142. Corey K. E., Kane E., Munroe C., Barlow L. L., Zheng H., Chung R. T., Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009 50 4 1030 1037 2-s2.0-70350044610 10.1002/hep.23219
143. Ramcharran D., Wahed A. S., Conjeevaram H. S., Evans R. W., Wang T., Belle S. H., Yee L. J., Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010 52 3 854 863 2-s2.0-77956634475 10.1002/hep.23796
144. Harrison S. A., Rossaro L., Hu K.-Q., Patel K., Tillmann H., Dhaliwal S., Torres D. M., Koury K., Goteti V. S., Noviello S., Brass C. A., Albrecht J. K., McHutchison J. G., Sulkowski M. S., Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010 52 3 864 874 2-s2.0-77956646681 10.1002/hep.23787
145. Angelico F., Francioso S., Del Ben M., Feole K., Carbone M., Pignatelli P., Violi F., Angelico M., Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Alimentary Pharmacology and Therapeutics 2009 30 5 444 451 2-s2.0-68249096833 10.1111/j.1365-2036.2009.04055.x
146. Petta S., Camma C., Di Marco V., Cabibi D., Ciminnisi S., Caldorella R., Licata A., Massenti M. F., Marchesini G., Craxi A., Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antiviral Therapy 2009 14 5 631 639 2-s2.0-69849109303
147. Li J. H., Lao X. Q., Tillmann H. L., Rowell J., Patel K., Thompson A., Suchindran S., Muir A. J., Guyton J. R., Gardner S. D., McHutchison J. G., McCarthy J. J., Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010 51 6 1904 1911 2-s2.0-77952730427 10.1002/hep.23592
148. Adinolfi L. E., Ingrosso D., Cesaro G., Cimmino A., D'Antò M., Capasso R., Zappia V., Ruggiero G., Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C. Hepatology 2005 41 5 995 1003 2-s2.0-17844385292 10.1002/hep.20664 (Pubitemid 40593907)
149. Toniutto P., Fabris C., Falleti E., Cussigh A., Fontanini E., Bitetto D., Fornasiere E., Minisini R., De Feo T., Marangoni F., Pirisi M., Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C. Liver International 2008 28 2 257 263 2-s2.0-38849203079 10.1111/j.1478-3231.2007.01591.x (Pubitemid 351201039)
150. Borgia G., Gentile I., Fortunato G., Borrelli F., Borelli S., De Caterina M., Di Taranto M. D., Simone M., Borgia F., Viola C., Reynaud L., Cerini R., Sacchetti L., Homocysteine levels and sustained virological response to pegylated-interferon α 2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver International 2009 29 2 248 252 2-s2.0-58149484038 10.1111/j.1478-3231.2008.01832.x
151. Petta S., Bellia C., Mazzola A., Cabibi D., Cammà C., Caruso A., Di Marco V., Craxì A., Ciaccio M., Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis 2012 12 465 472 2-s2.0-82155180139 10.1111/j.1365-2893.2011.01557.x
152. Lonardo A., Loria P., Leonardi F., Borsatti A., Neri P., Pulvirenti M., Verrone A. M., Bagni A., Bertolotti M., Ganazzi D., Carulli N., Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease 2002 34 3 204 211 2-s2.0-18344386388 10.1016/S1590-8658(02) 80194-3 (Pubitemid 34269566)
153. Li Y., Xu C., Yu C., Xu L., Miao M., Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. Journal of Hepatology 2009 50 5 1029 1034 2-s2.0-64549089599 10.1016/j.jhep.2008.11.021
154. Lee Y.-J., Lee H.-R., Lee J.-H., Shin Y.-H., Shim J.-Y., Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clinical Chemistry and Laboratory Medicine 2010 48 2 175 180 2-s2.0-76649083261 10.1515/CCLM.2010.037
155. Yamada T., Suzuki S., Fukatsu M., Wada T., Yoshida T., Joh T., Elevated serum uric acid is an independent risk factor for nonalcoholic fatty liver disease in Japanese undergoing a health checkup. Acta Gastro-Enterologica Belgica 2010 73 1 12 17 2-s2.0-77954921930
156. Xu C., Yu C., Xu L., Miao M., Li Y., High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS ONE 2010 5 7 2-s2.0-77955366821 10.1371/journal.pone.0011578 e11578
157. Ryu S., Chang Y., Kim S.-G., Cho J., Guallar E., Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism 2011 60 6 860 866 2-s2.0-79956067886 10.1016/j.metabol.2010.08.005
158. Lee J. W., Cho Y. K., Ryan M. C., Kim H., Lee S. W., Chang E., Joo K. J., Kim J. T., Kim B. S., Sung K. C., Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut and Liver 2010 4 3 378 383 2-s2.0-77957574094 10.5009/gnl.2010.4.3.378
159. Petta S., Cammà C., Cabibi D., Di Marco V., Craxì A., Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2011 34 7 757 766 2-s2.0-80052501527 10.1111/j.1365-2036.2011.04788.x
160. Afzali A., Weiss N. S., Boyko E. J., Ioannou G. N., Association between serum uric acid level and chronic liver disease in the United States. Hepatology 2010 52 2 578 589 2-s2.0-77955695124 10.1002/hep.23717
161. Pellicano R., Puglisi G., Ciancio A., Balzola F., Saracco G., Ciccone G., Baldi I., Abate M. L., Smedile A., Rizzetto M., Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection? Journal of Medical Virology 2008 80 4 628 631 2-s2.0-40549111664 10.1002/jmv.21123 (Pubitemid 351358560)
162. Petta S., Macaluso F. S., Cammà C., Di Marco V., Cabibi D., Craxì A., Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. Liver International 2012 32 1443 1450 10.1111/j.1478-3231.2012.02842.x
163. Feig D. I., Kang D.-H., Johnson R. J., Medical progress: uric acid and cardiovascular risk. New England Journal of Medicine 2008 359 17 1811 1821 2-s2.0-54949100735 10.1056/NEJMra0800885
164. Edwards N. L., The role of hyperuricemia in vascular disorders. Current Opinion in Rheumatology 2009 21 132 137 10.1097/BOR.0b013e3283257b96
165. Prokunina-Olsson L., Muchmore B., Tang W., A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature Genetics 2013 45 164 171